New Class of Glaucoma Drugs Show Promise
Rho kinase inhibitors are a new class of glaucoma drugs currently in clinical trials. Rho kinase (dubbed “ROCK”) inhibitors promise to act specifically on the eye’s drainage canals (called the trabecular meshwork) a main outflow and blockage site in glaucoma.